Dudelange (Luxembourg), Antwerp (Belgium), London (UK), Marcy l’Etoile (France), 4 April 2019 – IBBL (Integrated BioBank of Luxembourg) joins the consortium of VALUE-Dx, a prestigious Innovative Medicines Initiative (IMI) project aiming to combat antimicrobial resistance (AMR) and improve patient outcomes.
Diagnostics are deemed instrumental in guiding healthcare professionals in treating infectious diseases. However, in community care settings antibiotics are often overused and unnecessarily prescribed, accelerating AMR. VALUE-Dx is a European-wide approach aiming to generate evidence on the medical, economic, and public health value of diagnostics in tackling AMR.
The project will focus on acute respiratory tract infections acquired in community care settings as they are the most frequent cause of medical consultation and inappropriate antibiotic use. The outcomes of VALUE-Dx could apply to other common infections such as urinary tract infections, blood stream infections, and hospital-acquired respiratory tract infections. The purpose of VALUE-Dx is to transform medical practice to achieve more personalised, evidence-based antibiotic prescription and use in community care settings through the widespread use of clinical and cost-effective innovative diagnostic strategies.
The project consortium, coordinated by the University of Antwerp, includes 26 partners from academia, industry and other organisations. Specifically, IBBL will support the creation and maintenance of a biobank of clinical samples, pathogens and DNA isolated from Community-Acquired Acute Respiratory Tract Infections (CA-ARTI) patients, as well as the establishment of a database and repository of all data collected within VALUE-Dx. Moreover, IBBL will lead the development of a business plan for the creation and maintenance of a biobank of clinical specimens, strains and DNA.
“We are delighted to be part of such an interdisciplinary consortium and innovative study. The high quality of samples and data collected throughout the project will underpin its successful outcome. Through our proven expertise in biospecimen collection, processing and storage, we will support our partners in achieving this crucial task”, comments Dr. Fay Betsou, Chief Scientific Officer at IBBL.
The VALUE-Dx kick-off meeting took place in Madrid, Spain, from April 1st to April 4th, bringing together major stakeholders and key experts in the field of diagnostics and AMR.
VALUE-Dx is a European public-private partnership co-funded by the European Commission (under IMI), the Wellcome Trust and private companies, with a duration of 4 years. The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and well-being of all, especially in areas of unmet medical need.